Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more
Natco Pharma has withdrawn its compulsory license application for Baricitinib following an agreement with Eli Lilly. The Indian Patent Office has extended procedural deadlines, and other significant updates…